XORTX Logo.jpg
XORTX Announces Results of Annual and Special Meeting of Shareholders
September 13, 2024 07:00 ET | XORTX Therapeutics Inc.
CALGARY, Alberta, Sept. 13, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company...
XORTX Logo.jpg
XORTX Announces Re-filing of YE 2023 and Q2 2024 MD&A
September 12, 2024 17:30 ET | XORTX Therapeutics Inc.
CALGARY, Alberta, Sept. 12, 2024 (GLOBE NEWSWIRE) --  XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company...
XORTX Logo.jpg
XORTX Reminds Shareholders of Voting Deadline for Upcoming Annual and Special Meeting of Shareholders
September 06, 2024 17:30 ET | XORTX Therapeutics Inc.
CALGARY, Alberta, Sept. 06, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company...
XORTX Logo.jpg
Independent Proxy Advisory Firm ISS Recommends XORTX Shareholders Vote FOR ALL Proposed Items at the Upcoming Annual and Special Meeting of Shareholders
September 03, 2024 12:30 ET | XORTX Therapeutics Inc.
CALGARY, Alberta, Sept. 03, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company...
XORTX Logo.jpg
XORTX Highlights Pioneering Research Indicating a Role for Genetic Regulation of Xanthine Oxidase and Therapeutic Targeting of Aberrant Purine Metabolism
August 29, 2024 07:00 ET | XORTX Therapeutics Inc.
● Xanthine oxidase reported to modulate progression of chronic kidney disease, diabetic kidney disease, polycystic kidney disease, and other indications ● CALGARY, Alberta, Aug. 29, 2024 ...
XORTX Logo.jpg
XORTX Announces Filing and Mailing of the Meeting Documents in Connection with the Annual and Special Meeting of Shareholders
August 23, 2024 07:00 ET | XORTX Therapeutics Inc.
CALGARY, Alberta, Aug. 23, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company...
XORTX Logo.jpg
XORTX Announces Presentation at American Society of Nephrology – Kidney Week 2024
August 20, 2024 07:00 ET | XORTX Therapeutics Inc.
CALGARY, Alberta, Aug. 20, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA), a late-stage clinical pharmaceutical company...
XORTX Logo.jpg
XORTX to Present at BIO International Convention 2024
June 04, 2024 08:30 ET | XORTX Therapeutics Inc.
CALGARY, June 04, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on...
XORTX Logo.jpg
XORTX Reprices Balance of Warrants Issued in Connection with October 2021 US IPO
May 17, 2024 07:00 ET | XORTX Therapeutics Inc.
CALGARY, Alberta, May 17, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company...
XORTX Logo.jpg
XORTX Reprices Warrants Issued in Connection with Previous Private Placements
April 30, 2024 13:54 ET | XORTX Therapeutics Inc.
CALGARY, Alberta, April 30, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company...